156 related articles for article (PubMed ID: 37324525)
1. Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18-64 years.
Yogurtcu ON; Funk PR; Forshee RA; Anderson SA; Marks PW; Yang H
Vaccine X; 2023 Aug; 14():100325. PubMed ID: 37324525
[TBL] [Abstract][Full Text] [Related]
2. Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16-29 years.
Funk PR; Yogurtcu ON; Forshee RA; Anderson SA; Marks PW; Yang H
Vaccine; 2022 Apr; 40(19):2781-2789. PubMed ID: 35370016
[TBL] [Abstract][Full Text] [Related]
3. Incidence Rates and Clinical Characteristics of Patients With Confirmed Myocarditis or Pericarditis Following COVID-19 mRNA Vaccination: Experience of the Veterans Health Administration Through 9 October 2022.
Luo J; Hur K; Salone C; Huang N; Burk M; Pandey L; Thakkar B; Donahue M; Cunningham F
Open Forum Infect Dis; 2023 Jul; 10(7):ofad268. PubMed ID: 37469619
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
[TBL] [Abstract][Full Text] [Related]
5. Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
Fix J; Christopher Mast T; Smith K; Baker N
Vaccine; 2024 Apr; 42(9):2161-2165. PubMed ID: 38494410
[TBL] [Abstract][Full Text] [Related]
6. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L
BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976
[TBL] [Abstract][Full Text] [Related]
7. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
Abraham N; Spruin S; Rossi T; Fireman B; Zafack J; Blaser C; Shaw A; Hutchings K; Ogunnaike-Cooke S
Vaccine; 2022 Jul; 40(32):4663-4671. PubMed ID: 35750537
[TBL] [Abstract][Full Text] [Related]
8. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
Gargano JW; Wallace M; Hadler SC; Langley G; Su JR; Oster ME; Broder KR; Gee J; Weintraub E; Shimabukuro T; Scobie HM; Moulia D; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(27):977-982. PubMed ID: 34237049
[TBL] [Abstract][Full Text] [Related]
9. Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types.
Li M; Yuan J; Lv G; Brown J; Jiang X; Lu ZK
J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834458
[TBL] [Abstract][Full Text] [Related]
10. Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand.
Mahasing C; Doungngern P; Jaipong R; Nonmuti P; Chimmanee J; Wongsawat J; Boonyasirinant T; Wanlapakorn C; Leelapatana P; Yingchoncharoen T; Ngarmukos T; Chokephaibulkit K; Srimahachota S
Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112661
[TBL] [Abstract][Full Text] [Related]
11. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
Wong HL; Hu M; Zhou CK; Lloyd PC; Amend KL; Beachler DC; Secora A; McMahill-Walraven CN; Lu Y; Wu Y; Ogilvie RP; Reich C; Djibo DA; Wan Z; Seeger JD; Akhtar S; Jiao Y; Chillarige Y; Do R; Hornberger J; Obidi J; Forshee R; Shoaibi A; Anderson SA
Lancet; 2022 Jun; 399(10342):2191-2199. PubMed ID: 35691322
[TBL] [Abstract][Full Text] [Related]
12. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents.
Karlstad Ø; Hovi P; Husby A; Härkänen T; Selmer RM; Pihlström N; Hansen JV; Nohynek H; Gunnes N; Sundström A; Wohlfahrt J; Nieminen TA; Grünewald M; Gulseth HL; Hviid A; Ljung R
JAMA Cardiol; 2022 Jun; 7(6):600-612. PubMed ID: 35442390
[TBL] [Abstract][Full Text] [Related]
14. Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination-A nationwide study.
Su WJ; Liu YL; Chang CH; Lin YC; Huang WI; Wu LC; Chen SF; Lin YS; Hsieh YL; Yang CA; Lin CH; Chan KA; Lee PI; Chuang JH; Yang CH
J Microbiol Immunol Infect; 2023 Jun; 56(3):558-565. PubMed ID: 36804307
[TBL] [Abstract][Full Text] [Related]
15. Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy.
Corrao G; Franchi M; Cereda D; Bortolan F; Leoni O; Vignati E; Pavesi G; Gori A
BMC Infect Dis; 2022 Nov; 22(1):844. PubMed ID: 36371165
[TBL] [Abstract][Full Text] [Related]
16. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination.
Goddard K; Lewis N; Fireman B; Weintraub E; Shimabukuro T; Zerbo O; Boyce TG; Oster ME; Hanson KE; Donahue JG; Ross P; Naleway A; Nelson JC; Lewin B; Glanz JM; Williams JTB; Kharbanda EO; Katherine Yih W; Klein NP
Vaccine; 2022 Aug; 40(35):5153-5159. PubMed ID: 35902278
[TBL] [Abstract][Full Text] [Related]
17. Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations.
Alami A; Krewski D; Mattison D; Wilson K; Gravel CA; Villeneuve PJ; Farrell PJ; Crispo JAG; Perez-Lloret S
Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632478
[TBL] [Abstract][Full Text] [Related]
18. Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States.
Hatziantoniou S; Anastassopoulou C; Lazaros G; Vasileiou K; Tsioufis C; Tsakris A
Expert Rev Vaccines; 2022 Nov; 21(11):1691-1696. PubMed ID: 35815358
[TBL] [Abstract][Full Text] [Related]
19. Risk of myopericarditis following COVID-19 mRNA vaccination in a large integrated health system: A comparison of completeness and timeliness of two methods.
Sharff KA; Dancoes DM; Longueil JL; Johnson ES; Lewis PF
Pharmacoepidemiol Drug Saf; 2022 Aug; 31(8):921-925. PubMed ID: 35404496
[TBL] [Abstract][Full Text] [Related]
20. Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
Nasreen S; Calzavara A; Buchan SA; Thampi N; Johnson C; Wilson SE; Kwong JC;
Vaccine; 2022 May; 40(24):3305-3312. PubMed ID: 35527057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
